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Summary The two techniques of flow cytometry analysis (FCM) and immunohistochemical localisation of
bromodeoxyuridine (BrdUrd) incorporation after in vivo administration, were combined to study proliferation
in squamous cell carcinoma of the head and neck region. Care was taken in this study to ensure that similar
material was processed using both techniques such that comparisons could be made. FCM underestimated the
labelling index (LI) in tumours classified as diploid compared to the histological evaluation of the tumour cells
within those tumours (4.6% vs 17.1.%). However, in aneuploid tumours, the FCM LI (10.7%) was similar to
that obtained from histology (13.5%). Indeed, proliferation assessed by the combination of histology LI and
FCM duration of S-phase (Ts) indicated that diploid tumours had a shorter median potential doubling time
(Tp,,) of 2.1 days compared to aneuploid (2.8 days). Despite the heterogeneity of proliferation evident
histologically within the specimens, there was not a wide variation in the results of FCM analysis when
multiple samples from resections were studied. Using FCM data alone, 46% of the tumours showed a T,,, of
less than 5 days. When the Ts from the FCM data was combined with the average histological LI, 84% were
less than 5 days and with the maximum LI, 99% were within this time interval. Compared with previous
estimates, the proportion of tumours possessing proliferative characteristics which may indicate the need for
acceleration of treatment seems to be much larger.
Persistent or recurrent tumours remains a problem for many
patients with advanced cancer of the head and neck. Recent
evidence derived from the cellular kinetics of human tumours
and from analyses of clinical data has suggested that an
important cause for radiation failure may be cellular repopu-
lation during the course of treatment (Fowler, 1986; Withers
et al., 1988; Wilson et al., 1988).
Accelerated schedules of radiotherapy have been devised
which reduce the overall duration of treatment so as to
minimise the time for cellular repopulation (Peters et al.,
1988; Dische & Saunders, 1990). However, some reduction in
the total dose given to tumour may be necessary because of
an increase in acute normal tissue reactions. Although those
patients with tumours having a potential for rapid cellular
proliferation may benefit from the accelerated regime of
radiotherapy, those with slowly proliferating tumours may
not and, because the total dose given may be reduced, they
may be at disadvantage (Thames et al., 1983). A considerable
effort, therefore, has been directed to the prediction of
tumours likely to benefit from accelerated radiotherapy.
Attention has focused upon the cell kinetics of human
tumours and their possible prognostic significance (Wilson et
al., 1988; Begg et al., 1990). The growth of a tumour depends
upon three main parameters - the proportion ofproliferating
cells (the growth fraction), the duration of the cell cycle (Tc)
and the proportion of cells which fail to take part in further
cell devision (the cell loss factor). Steel (1977) introduced the
potential doubling time (Tpot), as a measure of the theoretical
proliferative capability of a tumour cell population in the
absence of any cell loss. It seems probable that early in a
course of radiotherapy, and also during chemotherapy, when
many tumour cells will have been killed, cell loss factors are
greatly altered and the potential cell doubling time of the
tumour may be realised.
Until recently, it has not been possible to measure easily
these parameters in human tumours because the determina-
tion of cell kinetics has required the administration of
radioactive DNA precursors such as tritiated thymidine
(3HTdR) with the need for multiple biopsies to construct a
pulse label mitosis analysis; in addition, many weeks are
required for the result to be obtained. Simple determination
of the LI can be performed by in vitro techniques using a
variety of methods, but all calculations derived from them
need to assume a cell cycle time.
Using bromodeoxyuridine (BrdUrd) and a technique deve-
loped by Begg et al. (1985), it is now possible to determine
tumour cell kinetics in human tumours simply, safely and
speedily. Using flow cytometry, the duration of S-phase (Ts)
and the labelling index (LI) can be measured from a single
sample and from these parameters, the Tpot is calculated.
Since 1985, we have been giving patients an intravenous
injection of BrdUrd 4 to 6 h prior to biopsy or surgical
removal and the series now extends to over 500 patients.
The administration of BrdUrd in vivo represents the best
mode to study DNA precursor incorporation as it is free
from the artifacts which can be associated with in vitro
incorporation. However, there are possibilities of variation
even in vivo because of poor diffusion and transient alteration
in the vascular perfusion.
Using flow cytometry, however, the prerequisite for a sin-
gle cell suspension loses information concerning spatial
heterogeneity and cellular identity, particularly in diploid
tumours where tumour cells cannot be differentiated from
normal cells. Using immunohistochemical techniques, it is
possible to visualise and estimate the BrdUrd labelling in
tumour cells in histological sections and to compare it with
that determined by flow cytometry. This paper reports the
finding by flow cytometry and by histological study after
BrdUrd administration, and discusses the implications of the
results for clinical radiotherapy.
Materials and methods
Case selection
Commencing in 1985, all patients with head and neck
tumours receiving radiotherapy in the Cancer Treatment
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Centre or surgery in the Plastic Surgery Centre at Mount
Vernon Hospital were considered for tumour cell kinetic
studies. This was performed whenever possible and always
with the patients' informed consent. Accessible tumours
within the oral cavity and oropharynx were usually sampled
under local anaesthesia, as also were secondary nodes in the
neck using a drill biopsy or Trucut needle. In other cases, an
opportunity for study often occurred at the time of an
examination under anaesthesia or at resection of tumour.
The dose of BrdUrd administered to patients, in this study,
was 200 mg by intravenous, bolus injection in 20 ml of nor-
mal saline. The desired interval between administration of
BrdUrd and the taking of the tumour sample was 4 to 6 h,
although in some cases, for practical reasons, longer intervals
elapsed.
The majority of biopsies under local anaesthesia were per-
formed by one operator (S.D.) and a consistent policy of
division of the sample was followed to ensure that the pieces
taken for histology and FCM were macroscopically similar.
A small portion was placed in formal saline for histological
study and the rest into 70% ethanol for cytokinetics. Where
a whole tumour was excised, the specimen was taken to the
Department of Histopathology, cut immediately by the path-
ologist and appropriate adjacent samples taken. Clinical data
was recorded and follow-up performed in all cases.
Out of a total of 502 patients studied with BrdUrd
between May 1985 and June 1991, 162 were in patients with
squamous cell cancers in the head and neck region. Of these,
123 cases are presented in which both FCM and immuno-
histochemical labelling have been assessed.
Flow cytometry
The flow cytometry methods of preparation and analysis
have been described in detail elsewhere (Wilson et al., 1988).
Briefly, ethanol-fixed tissue fragments were digested into
nuclei using 0.4 mg ml-' pepsin in 0.1 mol 1' HCl for 30 min
at 37°C. DNA was denatured with 2 mol I` HCl for 12 min
at room temperature. A 1:20 dilution of a rat anti-BrdUrd
antibody (Sera Labs, Crawley Down) in PBS containing
0.5% Tween-20 and 0.5% normal goat serum was incubated
with the nuclei for 1 h at room temperature. Fluorescence
was indirectly attached to the BrdUrd using a 1:20 dilution
of goat anti-rat IgG FITC conjugate (Sigma Chemical Co.,
Poole) for 30 min at room temperature. Total DNA was
stained using 10 g ml-' propidium iodide and the samples
analysed by FCM.
The majority of specimens were analysed on an Ortho
Systems 50-H Cytofluorograf, although some were analysed
using a Becton Dickinson FACScan. Both machines were
equipped with pulse processing facilities to discriminate cell
doublets. At least 10,000 events were collected in list mode.
The data derived from the FCM profiles were the DNA
index, the LI of all cells or the aneuploid subcomponent in
appropriate tumours making a simple correction for cell
division (Wilson et al., 1988), the Ts using the method of
Begg et al. (1985) and the Tpot using the formula
Tpt =,k Ts
LI
where A was assumed to be 0.8.
Histology
Specimens for histological examination were fixed in formal
saline and processed to paraffin wax blocks, 5 im sections
cut in the standard manner and mounted on poly-l-lysine
coated slides. One section was stained with haematoxylin and
eosin and from this the type of tumour and its grade were
determined, and also the proportions of tumour, normal
non-neoplastic tissues and necrosis or debris estimated. An
adjacent section was immuno-stained for BrdUrd using the
Avidin Biotin Complex (ABC) technique. Pretreatment with
0.1% trypsin in 0.1% calcium chloride for 13 min at 37°C,
followed by incubation in 1 mol I-' HCl for 15 min at 37°C
was required to expose the binding sites for BrdUrd. The
monoclonal antibody used in these studies was mouse anti-
BrdUrd (Dakopatts, High Wycombe, England) at 1:30 in
Tris buffered saline containing 1% human AB serum. The
monoclonal antibody against BrdUrd was different to that
used in the FCM studies, as mouse determinants are
routinely used in the ABC method.
All stained sections were quantitated by assessment of the
whole specimen using a visual estimate, whilst 15 (about
10%) were also counted using a graticule for comparison.
The visual technique involved selecting low power areas of
lowest and highest labelling of the tumour cells. One high
power field ( x 40 objective x 10 eyepiece) of each of these
areas was counted using a video system with a grid on the
screen or with a square graticule filling half the diameter of
the field. In both methods, the field contained between 50
and 200 tumour cells, depending on their size and density.
The specimen was then carefully scanned and an estimate of
average tumour cell LI made based on the maximum and
minimum LI's and the distribution of these throughout the
specimen. In addition, the pattern of staining, which gave an
indication of heterogeneity, was also assessed (see Figure 2).
In 15 cases, labelling was assessed by point counting using
alternate high power fields ( x 40 objective x 10 eyepiece)
and a square graticule. The field contained 50 to 350 tumour
cells, such that 10 to 20 high power fields were counted for
each specimen to obtain a minimum of 2,000 cells. The
average LI was calculated as the total number of BrdUrd
labelled cells vs the total tumour cells counted. Standard
errors were computed from the variation between high power
fields.
There was considerable heterogeneity in the intensity of
BrdUrd labelling both within and between specimens. How-
ever, the discrimination of even lightly labelled cells from
those which were not labelled was straightforward due to
manipulation of the haematoxylin staining.
The histology LI does not take into account cell division
between injection and biospy. A correction for this was made
using the FCM data in which the fraction of BrdUrd labelled
cells which have either divided or remain undivided is
known. The histology LI was corrected by a simple propor-
tion from the uncorrected and corrected FCM LI by:
ucorrected LI (FCM) corrected LI (hist) = uncorrected LI((FCM) x uncorrected LI (hist)
Results
Comparison ofpoint counting and visual estimation of
histological LI
Figure 1 shows the correlation between high power field
counting and the visual estimate of LI on tissue sections.
There was a highly significant correlation (r2= 0.93,
P< 0.0001) with a slope of 0.91.
Data obtainedfrom histology andFCM
Figure 2 shows examples of staining profiles obtained from
immunohistochemistry. Four different staining patterns were
observed and these were denoted marginal, intermediate, ran-
dom and mixed, i.e. when more than one of the other
patterns were observed. Marginal staining was most com-
monly found in grade 1 tumours and random in grade 4,
with intermediate patterns in grades 2 and 3. Four examples
have been chosen to illustrate different staining patterns.
Figure 2a shows a grade 1 tumour of the tongue showing
marginal staining when only the cells at the margin of the
tumour cords and masses were labelled. In this specimen, the
corrected average LI was 17.4%. This was in contrast to the
FCM data, in which the LI was only 3.9% (Figure 3a). The
tumour was diploid and had a Ts of 9.1 h, resulting in a Tpot
of 7.8 days. The discrepancy in LI may be explained by the
histological observation that only 20% of the specimen was
occupied by tumour cells, the other 80% being stromal cells.872 M.H. BENNETT et al.
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Figure 1 Correlation between point counting and the visual
estimate method for the assessment of BrdUrd LI on histological
sections. The data represent the observed value for the visual
method and the overall mean value for point counting. The bars
represent s.e.m.'s calculated from all the high power fields. No
correction for cell division has been made.
Figure 2b shows an example of an intermediate staining
pattern in which several layers of cells around the margin are
labelled. This was a grade 3 tumour of the upper alveolus
which had an average LI of 13.4%. This LI agreed well with
that from FCM (Figure 3b), 11.8%, as the tumour was
aneuploid with a DNA index of 1.85. The Ts and Tpot were
9.9 h and 2.8 days respectively.
The other distinct pattern, random, is shown in Figure 2d,
in which labelled cells were scattered throughout. The exam-
ple shows a grade 4 tumour of the lower alveolus in which
the histology LI was 28%, whilst FCM (Figure 3d) gave a
value of 17.2%. The LI and Ts of 10.3 h combined to give a
rapid Tpot of only 2.0 days.
The mixed patterns usually correlated with tumours show-
ing areas of differing degrees of differentiation, but the grade
given with each tumour was for the most poorly differen-
tiated area. Figure 2c shows a grade 3 tumour of the tonuge
with a LI of 20.1%. In this tumour some areas showed
moderate differentiation with an intermediate labelling pat-
tern, although many layers ofcells in the periphery of the cell
mass were labelled. Other less differentiated areas (arrowed)
show a random labelling pattern. FCM (Figure 3c) revealed
an aneuploid tumour (DNA index 1.85) with a LI, Ts and
Tpot of 16.8%, 13.4h and 2.7 days respectively.
Distribution ofproliferation parameters
Table I shows the median values obtained for the parameters
studied for each group of tumours. There are no important
differences in proliferation characteristic between primary,
recurrent or metastatic disease, although the numbers in
some groups are small.
Within each of the parameters measured there was a wide
distribution of values as indicated by the numbers in paren-
theses in Table I (the coefficients of variations for all
tumours) and from Figure 4. Figure 4 shows the distribution
of FCM LI, Ts, Tpot and average histological LI in primary
tumours only. Flow cytometry derived LI varied from 0.9 to
20.4%, whilst that obtained from histology ranged from 1.8
to 45.2%. The variation in LI was expected but Ts also
showed a wide variation ranging from 5.4 to 24.3 h. The two
FCM parameters yield the Tpot which can be from as short as
1.8 days to 41.2 days. This parameter shows most variation
as judged by the C.V. of 82%.
Influence ofsite on proliferation parameters
The major sites studied in the head and neck classified ac-
cording to grade, DNA index, Tpot and average LI assessed
histologically, are shown in Figure 5. When the sites are
compared in order from lip to tonsil, there is a trend for the
proportion of low grade tumours to decrease and for the
incidence of aneuploidy to increase. At the columella, there
was also a high incidence of aneuploidy. There was no
significant relationship between proliferation characteristics
and site. Tumours of the columella and floor of mouth
tended to show the slowest proliferation when assessed flow
cytometrically, but this discrimination was not apparent
when histology was used to calculate LI. Both methods
agreed that tumours arising in the tonsil region tended to be
rapidly proliferating.
Relationship between proliferation, histological grading and
clinical staging
Figure 6 relates grade and T staging to proliferation. None
of the proliferation parameters, FCM LI, Ts, Tpo,t average LI
or maximum LI showed any significant relationship with
histopathological grading. Interestingly, grade 4 tumours
tended to be diploid and they were inclined to be more
slowly proliferating than grades 2 and 3 when assessed by
FCM. However, histologically, the proportion of BrdUrd
labelled cells was higher in grade 4 tumours in which the
median histology LI was 22.4% compared to 11.8, 15.7 and
13.9 in grades 1, 2 and 3 respectively.
Clinical staging also had little relationship to proliferative
characteristics. Only two patients presented T, tumours and
the median Tpots for T2, T3 and T4 were 4.8, 5.9 and 4.6 days
respectively. Histological evaluation of LI suggested that the
tumour cell LI may be lower in T2 tumours, in which the
median values was 9.6%, compared to 16.4 and 16.5% in
stages 3 and 4. There were no apparent relationships between
N stage and proliferative characteristics, median Tpts were
6.0, 4.8, 4.9 and 5.4 days, in No, N,, N2 and N3 respectively
and the histology LI's were 13.7, 16.7, 16.3 and 12.7% within
these categories.
Influence ofDNA index on proliferation
As expected, FCM analysis suggested that diploid tumours
have a lower LI than aneuploid tumours (median values 4.6
and 10.7% respectively) (Figure 7). However, this difference
did not exist when in histological evaluation only the tumour
cells were assessed. In fact, the average histological LI was
slightly greater in diploid (17.1%) than aneuploid tumours
(13.5%), where the value was of the same order as that for
LI by FCM (10.7%). Ts was slightly shorter in diploid (9.0 h)
than aneuploid tumours (11.7 h). When the Tt was calcul-
ated from the FCM data, diploid tumours appear to be more
slowly proliferating (6.8 days) than aneuploid (3.9 days).
However, if the average histological LI was used in conjunc-
tion with FCM Ts for each tumour, the median Tpot in
diploid tumours was only 2.1 days and was faster than that
found in aneuploid tumours (2.8 days).
Heterogeneity ofproliferation assessed by FCM
Heterogeneity was assessed in eight patients, whose tumours
were resected, by taking 4 and 9 (mean 6) individual biopsy-
like fragments from the tumours and staining and assessing
each one by flow cytometry.
As expected, each proliferation parameter showed varia-
tion as judged by the coefficient of variation (CV). However,
the variations were not large. The average CY's for LI, Ts
and T.., were 26.8%, 15.1% and 30.3% respectively (c.f.
Table I). The individual data for the Tpot, are shown in
Figure 8. The mean Tpot spanned from 1.85 days to 8.32
days. It is apparent that few tumours would be wrongly
classified as fast or slow (in this case above or below a Tpot of
5 days) unless their mean value was close to the cut-offvalue.
There was evidence of DNA index variation in only two of
these eight tumours. In two tumours, all observations were
diploid, in a further four, all observations were aneuploid
with similar DNA indices within each tumour. Two tumoursPROLIFERATION IN HEAD AND NECK CANCER 873
M.
Figure 2 Immunohistochemical localisation of BrdUrd in four squamous cell cancers of the head and neck. The H and E and immunoperoxidase staining patterns from adjacent sections are shown for a tumour showing a, a marginal (magnification x 140), b, intermediate (magnification x 400), c, mixed (magnification x 100), and d, random staining pattern (magnification x 170). For explanation of the staining patterns, see text.874 M.H. BENNETI? et al.
6 100
_ 80
> 40
.20
0 20 40 60 80 100
DNA content
6 100
80-
a 60
a)
'o20 L
0 20 40 60 80 100
DNA content
100
8 00
60[.-
a)
> 4
20
0o 2040 60 80100
DNA content
DNA content
0)100
X80
t60 -Aj
240
0 20 40 60 80 100
DNA content
100
m 800[
~60
-
~240. ~ ~ ~
E 20
0 20 40 60 80 100
DNA content
6
c
0
a)
a:-
DNA content DNA content
Figure 3 Corresponding flow cytometric distributions of BrdUrd
and total DNA content in the four tumours presented in Figure 1.
showed two or more DNA indices. In one of these, five of six
pieces were diploid and one was tetraploid. In the other
tumour, one piece was diploid, one was tetraploid, one had a
DNA index of 1.9 and the remaining three were close to 1.8.
Discussion
The incorporation of BrdUrd into human tumours in vivo
has facilitated the study of cell kinetics. Potential cell doub-
ling times can be estimated from a single biopsy taken several
hours after the injection of BrdUrd using flow cytometric
techniques. However, the major drawback of FCM is the loss
of morphological cellular identity and the possibility that cell
selection may occur. These limitations present a particular
problem in tumours classified as diploid by FCM, in which
discrimination of normal and tumour cells is not possible. In
this study using immunohistochemical localisation of pro-
liferating cells in histological sections of adjacent comparable
specimens, we were able to identify the cellular composition
of the tissue examined.
The choice of the visual method to assess LI on tissue
sections was made because point counting of 10 to 20 high
power fields to achieve a total count of 2,000 cells may only
examine a fraction of the whole specimen. It will also be
highly dependent on the choice of fields if there is variability
and structure to the labelling patterns, as is found in the
better differentiated squamous cell cancers. The visual
method, like FCM, studies the whole specimen. The techni-
que involves quantitation of maximum and minimum labell-
ing areas and a careful assessment of the distribution of
labelling throughout the whole specimen. The correlation in
Figure 1, between point counting and the visual estimate,
justifies the approach used in this study. However, it should
be recognised that this method would not be suitable for
counting mitoses where the mitotic index may be less than
1%.
The addition of histological evaluation of proliferating
cells to the results of FCM in squamous cell cancer of the
head and neck reveals that there is no systematic difference in
proliferation between diploid and aneuploid tumours (Figure
7). The average LI of diploid tumours was 17.1% and of
aneuploid tumours 13.5%. The Tpo, was calculated using the
individual histology derived LI and the flow cytometry deriv-
ed Ts. Figure 9 shows the correlation between the hybridrised
Tp,t and that derived purely from FCM. There is good
agreement in aneuploid tumours between two approaches.
This result suggests that cell selection is not a problem with
the FCM technique, but proliferation in diploid tumours is
underestimated by FCM alone. This calls into question the
validity of conclusions drawn from kinetic studies, particular-
ly those where data is available only from DNA S-phase
fractions, which suggest that diploid tumours are more slow-
ly proliferating (Johnson et al., 1985). Clearly this is not the
case for head and neck tumours, and we have seen, in
preliminary review, that neither is it so in oesophageal or
lung carcinoma. Because diploid tumours tended to have a
shorter Ts than aneuploid tumours (a measurement which
should not be greatly compromised by differences in the
detection of labelled cells by FCM), the median TP,,, deter-
mined using average histological LI, was shorter in diploid
tumours at 2.1 days compared to 2.8 days for the aneuploid.
The finding that diploid tumours are not more slowly pro-
liferating than aneuploid tumours may seem surprising. How-
ever, there is no direct evidence in the literature to suggest
that this may not be the case; studies involving 3HTdR LI
have not incorporated FCM analysis of DNA content, and
DNA S-phase fraction analysis alone is not appropriate for
the reasons outlined in this manuscript. Indirect evidence
comes from the difference in response of diploid or aneuploid
tumours to radio- or chemotherapy, but any difference can-
not be attributed solely to a difference in proliferation.
There was a trend for low grade tumours and the lower
LI's to be found at the front of the mouth compared to those
originating further back, but our results did not not suggest
any strong relationship between the site of the tumour within
the head and neck and proliferation assessed either by FCM
or by histology. These results are in agreement with Chauvel
et al. (1989) using 3HTdR. In our study, and that of Chauvel
et al. (1989) and Johnson et al. (1985), there was no relation-
ship between grading and proliferation.
The choice of technique to assess cell kinetics will have
profound influence on the proliferative classification of indi-
vidual tumours. In this study, the ranking of patients differs
if FCM is used alone compared to FCM and histology,
Table I Median values for each proliferation parameter in primary and recurrent head and neck cancer. The numbers in
parentheses represent the coefficient of variation for each parameter for all tumours
LI Ts TPF1I Ave LI Max LI %
Group No. (%) (h) (days) (%) (%) Aneuploid
All 123 6.8 (66) 9.9 (33) 5.7 (82) 14.9 (58) 33.9 (40) 41
Untreated
primary 91 6.9 9.7 5.2 14.5 33.8 41
neck nodes 9 5.4 11.4 7.7 20.9 27.0 33
Recurrent
primary 13 6.8 12.3 6.1 9.4 36.0 46
neck nodes 3 6.2 11.1 3.7 6.0 22.2 66
distant metastases 7 4.8 9.9 6.3 17.6 43.1 43
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Figure 4 Distribution of proliferation parameters in primary cancer of the head and neck.
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Figure 5 Influence of tumour site. The distribution of histological grading and DNA aneuploidy, and median Tpot and average
histological LI, presented for each of the major sites for primary tumours studied.
mainly due to difference in classification of diploid tumours.
However, if histological LI is used alone, which would be
analogous to studies employing in vitro 3HTdR incorporation
and autoradiography, there is also a difference in ranking
compared to the combination of FCM and histology. This is
because Ts shows wide variation in this and every other
group of human tumours we have studied. Figure 4 shows
that Ts can be as short as 5.4 h and as long as 24.3 h in head
and neck tumours. In addition, diploid tumours tended to
have a shorter Ts than aneuploid tumours. In vitro labelling
with BrdUrd or 3HTdR is inadequate to fully characterise the
cellular kinetics of solid tumours.
The intravenous administration of BrdUrd to patients for
tumour cell kinetic study has been questioned as a safe
procedure. It is a cytotoxic drug which remains under study
as a radiosensitiser (Mitchell et al., 1986). The dose of
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Figure 7 The influence of DNA aneuploidy on proliferation parameters. The data represent median values for each parameter for
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200 mg currently employed for this diagnostic procedure can
be compared with 7-10 gram commonly used with satisfac-
tory tolerance therapeutically. In the administration of
BrdUrd, in current dosage, to over 500 patients, no immed-
iate or late effect has been observed.
The uptake of BrdUrd in tumour cells after in vivo admini-
stration will depend upon drug distribution, diffusion and
upon the integrity of the vascular supply within the tumour.
In vitro labelling is also subject to diffusion problems, but
more importantly upon the viability of cells in isolated tissue.
The quantitation of in vitro labelled tissue fragments is also
more subjective as often only peripheral areas can be scored.
However, the only study which has compared in vitro and in
vivo labelling in squamous cell carcinomas of the head and
neck, using 3HTdR, found no systematic difference between
the two methods in the estimation of LI (Chavaudra et al.,
1979). If anything, the in vitro method slightly underesti-
mated the LI. In addition, their median LI's (17.0% in vivo,
11.5% in vitro) were similar to that obtained in this present
study using BrdUrd and histology (14.9%).
Heterogeneity is a valid criticism levelled at techniques
which rely on biopsy material particularly, as in the case of
the FCM method, when a temporal measurement (Ts) is
being made from one observation. It was not possible to
study heterogeneity using FCM in more than a small propor-
tion of our cases, as much of the material was obtained by
biopsy. However, in the eight specimens where multiple sam-
ples were studied, heterogeneity of the FCM-derived pro-
liferation parameters was surprisingly small. The Ts in partic-
ular proved to be the least variable, with six of the eight
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observations were made. A cut-off line has been drawn through a
Tpot of 5 days to indicate 'rapid' and 'slow' tumours.
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Figure 9 The correlation between Tpo, calculated by FCM alone
or average histological LI and FCM Ts in diploid (open symbols)
and aneuploid (closed symbols) tumours.
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Figure 10 Cumulative frequency of Tputmeasured by FCM
alone (O) or a combination of average (O) or maximum (A)
histological LI and FCM Ts. The numbers represent the percen-
tage of tumours with Tpots less than 1, 2, 3, 4, or 5 days.
tumours showing C.V.'s less than 20%. With the counting of
10,000 to 20,000 cells, the marked variation in labelling seen
histologically would seem to be overcome and the result
confirms the reproducibility of the single measurement. As
expected, the greatest variation was seen in the LI. These
results are similar to those reported by Begg et al. (1988) in a
series of seven squamous cell tumours from different sites.
The overall CV of the Tpot values, derived from two to seven
pieces, was 23.1%. The studies of heterogeneity show that
classification of a tumour as fast or slow would not be
modified in the majority of squamous cell cancers of the head
and neck if only one biopsy had been taken. This is in
contrast to studies in colorectal cancer in which substantially
more heterogeneity was observed (Rew et al., 1991) and in
bladder (Begg et al., 1988) using similar techniques.
Flow cytometry measured a 2- to 3-fold maximum varia-
tion in LI of the multiple analysis specimens, but the LI,
evaluated histologically, often showed a 4- to 10-fold varia-
tion between maximum and minimum labelling. There was
little or no labelling seen in differentiating cells resulting in
marked heterogeneity of labelling between microscope fields,
especially in the more differentiated tumours.
The parameter which may best predict the repopulation
potential of tumours is the doubling time of clonogenic cells
within that tumour (Thames et al., 1983). It has been sug-
gested that the CHART schedule with the treatment period
reduced to only 12 days, but with a reduced total dose, may
only benefit the tumours with the highest repopulation poten-
tial, i.e. with the clonogen doubling times of 3 days or less,
and that it should be less effective against tumours with
longer clonogen doubling times (Fowler et al., 1990). In
Figure 10 it can be seen that the combination of histology
and FCM predicts that almost two-thirds of tumours have
Tpots less than 3 days, whilst 84% have Tpots less than 5 days.
This suggests that CHART may be effective in the large
majority of squamous cell cancer in the head and neck. The
promising results seen in 99 such patients in the pilot study
give some confirmation (Saunders et al., 1991).
Within virtually every tumour studied by immunohisto-
chemistry, there were foci containing populations of cells
which appeared to be proliferating at a fast rate as judged by
the maximum histology LI obtained from a high power field.
It must be acknowledged that there is an element of subjec-
tivity in the selection of the field. However, it does seem
likely that it is these areas which are usually at the growing
edge of the tumour, and where the Tpot might only be 1 day,
which are an important cause for failure of conventional
protracted radiotherapy. The implication for therapy is that
many more tumours may have proliferative characteristics
which may benefit from shorter overall treatment times than
was suspected from using FCM alone.
This study demonstrates the value of combining histology
and flow cytometry to measure proliferation. Neither gives
the complete information by itself; it is the integration of the
two methods which may provide the best proliferative in-
formation which may be used to select patients for acceler-
ated treatment schedules.
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